GlassScriptPhysician profile
Megan C Case
NPI 1598172215
$16,751.37
in general payments reported to CMS, 2019-2025
28 companies · $763 in 2025
The $763 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $1,074 · 2023: $683 · 2024: $521 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,707.77 | 2021-2025 | |
| Amgen INC. | $4,695.33 | 2021-2023 | Aimovig |
| Allergan, INC. | $2,570.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $450.91 | 2021-2023 | Ajovy |
| Abbott Laboratories | $293.99 | 2024-2025 | Proclaim, Eterna |
| Currax Pharmaceuticals LLC | $253.52 | 2021-2023 | Onzetra Xsail, Contrave |
| Nevro Corp. | $249.28 | 2022-2024 | Senza |
| Globus Medical, INC. | $226.17 | 2025 | Senza |
| Biohaven Pharmaceuticals, INC. | $140.79 | 2021 | |
| Saluda Medical Americas, INC. | $140.41 | 2025 | Evoke |
| Nalu Medical, INC. | $127.04 | 2025 | Nalu Neurostimulation System |
| Novartis Pharmaceuticals Corporation | $116.81 | 2021 | |
| Lundbeck LLC | $107.88 | 2021-2023 | Vyepti |
| Lilly USA, LLC | $86.61 | 2022-2023 | Reyvow, Emgality |
| Impel Pharmaceuticals INC. | $86.19 | 2023 | Trudhesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $83.37 | 2021-2022 | |
| Pfizer INC. | $61.01 | 2021-2023 | |
| Medtronic, INC. | $59.51 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $47.86 | 2022 | |
| Ge Healthcare | $41.69 | 2021-2024 | |
| Ucb, INC. | $41.61 | 2021-2023 | Briviact |
| Sk Life Science, INC. | $34.30 | 2021-2022 | |
| Boston Scientific Corporation | $28.88 | 2024 | Wavewriter Alpha Prime 16 |
| Averitas Pharma INC. | $23.21 | 2024 | Qutenza |
| Ipsen Biopharmaceuticals, INC | $21.45 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $20.77 | 2025 | |
| Novo Nordisk INC | $19.65 | 2023 | Wegovy |
| Octapharma USA, INC. | $15.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.